India's Hetero labs launches COVID-19 drug 'Favipiravir', under brand name ‘Favivir’

July 29, 2020: Hyderabad-based Hetero Labs announced the launch of generic anti-viral drug favipiravir in India for Covid treatment on Wednesday.

DY365
DY365

July 29, 2020: Hyderabad-based Hetero Labs, one of India’s leading generic pharmaceutical companies and the world’s largest producer of antiretroviral drugs, announced the launch of generic anti-viral drug favipiravir in India for Covid treatment on Wednesday. 

Hetero has launched it under the brand name ‘Favivir’. It will be used for the treatment of mild to moderate coronavirus patients.

The drugmaker has already secured manufacturing and marketing approval for favipiravir from the Drug Controller General of India (DCGI).

The drug will be priced at 59 rupees per tablet and will be available at drug stores from Wednesday. However, a mandatory prescription is needed to obtain the drug. 

Related Links